Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of “Moderate Buy” by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $44.8333.

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. HC Wainwright boosted their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Citizens Jmp assumed coverage on Avalo Therapeutics in a research report on Monday, April 6th. They issued an “outperform” rating and a $52.00 price target for the company. Finally, Guggenheim assumed coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total value of $136,857.00. Following the completion of the transaction, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 46,100 shares of company stock valued at $764,724. Corporate insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new position in Avalo Therapeutics during the 4th quarter valued at about $1,150,000. XTX Topco Ltd increased its position in Avalo Therapeutics by 190.0% during the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after buying an additional 26,508 shares in the last quarter. Squadron Capital Management LLC acquired a new position in Avalo Therapeutics during the 4th quarter valued at about $2,361,000. SummitTX Capital L.P. acquired a new position in Avalo Therapeutics during the 4th quarter valued at about $3,557,000. Finally, Millennium Management LLC increased its position in Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after buying an additional 522,548 shares in the last quarter. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Trading Down 10.8%

Shares of AVTX stock opened at $12.86 on Wednesday. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The stock has a market capitalization of $343.49 million, a price-to-earnings ratio of -2.24 and a beta of 0.93. The stock has a fifty day simple moving average of $15.38 and a two-hundred day simple moving average of $16.23.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. Research analysts predict that Avalo Therapeutics will post -4.04 EPS for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.